Abstract

Proteolysis-targeting
chimeras (PROTAC) is a new technology which utilisies the intracellular
ubiquitin-proteasome system to induce targeted protein degradation. This
approach is receiving much attention in the field of targeted therapies
particularly in oncology with the added potential to eliminate targets which
have previously proved undruggable.

We have
conducted studies with a number of PROTAC target molecules using the Wes system
(Protein Simple) for quantitation. We will give examples of our experiences and
learning points.